<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124328">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01844973</url>
  </required_header>
  <id_info>
    <org_study_id>M518101-US05</org_study_id>
    <nct_id>NCT01844973</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho North America Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho North America Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the pharmacokinetics and safety of M518101 in male and female
      plaque psoriasis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of M5181</measure>
    <time_frame>0, 1, 2, 4, 6, 9 12h after dosing</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma concentration (Cmax) of M5181</measure>
    <time_frame>0, 1, 2, 4, 6, 9 12h after dosing</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>M518101</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>M518101</intervention_name>
    <description>Proper quantity twice a day</description>
    <arm_group_label>M518101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Proper quantity twice a day</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Who are able and willing to give signed informed consent

          -  Who are male or females aged 18 years or older with plaque psoriasis confirmed by the
             Investigator.

          -  Who have â‰¥20% of body surface area (BSA) afflicted with plaques

          -  Who are neither pregnant nor breast-feeding, nor plan to become pregnant during the
             study.

        Exclusion Criteria:

          -  Who have a history of allergy to vitamin D3 derivative preparations or a history of
             relevant drug hypersensitivity.

          -  BMI &gt; 32.0 kg/m2

          -  Who are pregnant or lactating.

          -  Who have any renal or hepatic insufficiency, or clinically significant cardiac, renal
             or hepatic disease.

          -  Who are not deemed eligible as determined by medical history, physical examination or
             clinical laboratory safety tests.

          -  Who have clinically relevant history or presence of any disease or surgical history
             other than psoriasis which is likely to affect the conduct of the study.

          -  Whose serum calcium levels exceed the upper limit of reference range

          -  Who have used any investigational medicinal product and/or participated in any
             clinical study within 60 days of randomization.

          -  Who have taken any durg with known effects on calcium metabolism within 30days of
             randomization

          -  Who have been treated with any drug with a known risk of QT prolongation within
             30days of randomization.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orenge County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 15, 2013</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
